For older t‐AML patients and young patients with comorbidities not eligible for IC and/or Allo‐HCT, HMA or cytarabine associated to venetoclax with or without targeted therapies (FLT3, IDH inhibitors, or anti‐CD47 antibody especially for TP53 mutated patients) seems to be the best therapeutic option. This evidence concerns the gene FLT3 and acute myeloid leukemia.